更新于：2024-11-01

Facial Hypertrichosis

面部多毛症

更新于：2024-11-01

基本信息

别名

FACIAL HYPERTRICHOSIS、Facial Hypertrichosis、Facial hypertrichosis

+ [2]

简介

Excessive, increased hair growth located in the facial region. []

关联

项与面部多毛症相关的药物

Eflornithine Hydrochloride

依氟鸟氨酸

靶点

ODC

作用机制

ODC抑制剂

在研机构

Panbela Therapeutics, Inc. [+8]

原研机构

Sanofi

在研适应症

高风险神经母细胞瘤 [+9]

非在研适应症

面部多毛症 [+1]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期1990-11-28

项与面部多毛症相关的临床试验

TCTR20220205004 / Completed临床4期IIT

Efficacy and Safety of Topical 3% Minoxidil for Facial Hair Enhancement in Transmen: A Randomized, Double-blind, Placebo-controlled Trial

开始日期2022-02-01

申办/合作机构-

EUCTR2005-003537-41-DE / Unknown statusN/A

Efficacy of the treatment with VANIQA 11,5% creme in patients suffering from hirsutism of the upper lip - Treatment with VANIQA

开始日期2005-10-27

申办/合作机构

Tricholog GmbH

100 项与面部多毛症相关的临床结果

登录后查看更多信息

100 项与面部多毛症相关的转化医学

登录后查看更多信息

0 项与面部多毛症相关的专利（医药）

登录后查看更多信息

项与面部多毛症相关的文献（医药）

2024-01-01·Journal of Clinical Sleep Medicine

Surgical correction of neonatal obstructive sleep apnea due to a temporomandibular joint ankylosis

作者: Goldbart, Aviv ; Givol, Navot ; Pesis, Michael

In growing children, temporomandibular joint (TMJ) ankylosis and septic arthritis are uncommon. Retrognathia and micrognathia affect airway patency and can cause obstructive sleep apnea (OSA). No unified diagnostic criteria have been established for the management of this pathology. We describe the first case of treatment for pediatric TMJ ankylosis and severe OSA due to neonatal group B streptococcal septic TMJ arthritis. Untreated pathological changes in the TMJ will eventually lead to ankylosis. Among children, this will include facial growth disturbances leading to mandibular retrognathia, reduction in the oropharyngeal spaces, and OSA. Our patient had severe OSA with an apnea-hypopnea index of 24.9 events/h and oxygen saturation nadir of 73% as measured by polysomnography. She was treated successfully according to Andrade protocol. This is the first report of pediatric OSA due to TMJ ankylosis following neonatal group B streptococcal septic arthritis.CITATIONPesis M, Goldbart A, Givol N. Surgical correction of neonatal obstructive sleep apnea due to a temporomandibular joint ankylosis. J Clin Sleep Med. 2024;20(1):173-179.

2023-09-15·Journal of clinical medicine

The Slavcleft: A Three-Center Study of the Outcome of Treatment of Cleft Lip and Palate Considering Palatal Shape.

Article

作者: Kotova, Magdalena ; Urbanova, Wanda ; Brudnicki, Andrzej ; Polackova, Petra ; Petrova, Tereza ; Dubovska, Ivana ; Fudalej, Piotr S ; Voborna, Iva

The degree of deviation of palatal shape from the norm may reflect facial growth disturbance in cleft lip and palate (CLP). The objective of this study was to compare the palatal morphology in children treated with different surgical protocols. Palatal shape was assessed with geometric morphometrics (GM) including Procrustes superimposition, principal component analysis (PCA), and permutation tests with 10,000 permutations, in 24 children treated with two-stage repair with a late palatoplasty (Prague group; mean age at assessment 8.9 years), 16 children after two-stage repair with early palatoplasty (Bratislava group; mean age 8.2 years), and 53 children treated with a one-stage repair (Warsaw group, mean age 10.3 years). The non-cleft control group comprised 60 children at 8.6 years. The first five principal components (PCs) accounted for a minimum of 5% of the total shape variability (65.9% in total). The Procrustes distance was largest for the Prague vs. Control pair and smallest for the Prague vs. Bratislava pair. Nonetheless, all intergroup differences were statistically significant (p < 0.01). One can conclude that variations in palatal shape roughly correspond to cephalometric and dental arch relationship findings from prior research. Among the children who underwent a one-stage repair of the complete cleft, their palatal morphology most closely resembled that of the non-cleft controls. Conversely, children who received late palatoplasty exhibited the greatest degree of deviation.

2023-08-16·Cureus

The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Pattern Hair Loss: A Systematic Review and Meta-Analysis

Review

作者: Aleissa, Majed

Oral spironolactone has been proposed as a potential treatment for hair loss due to its antiandrogenic properties. However, the efficacy and safety of spironolactone for treating hair loss are not well-established. The objective of this study was to conduct a systematic review of the current literature on the use of oral spironolactone in female pattern hair loss. We conducted a systematic review and meta-analysis of randomized controlled trials and observational studies that assessed the efficacy and safety of oral spironolactone for treating hair loss. We searched for eligible papers in PubMed, Web of Science (ISI), Embase, and Scopus. All analyses were done using R software version 4.2.3 (R Foundation for Statistical Computing, Vienna, Austria). The overall rate of improved hair loss was 56.60%, with a higher rate of improvement (65.80%) observed in the combined therapy group compared to the monotherapy group (43.21%). However, there was significant heterogeneity in the efficacy outcomes, and hair loss did not improve or showed a modest improvement in 37.80% of all patients. The rates of adverse events reported in at least two studies were scalp pruritus or increased scurf (18.92%), menstrual disorders (11.85%), facial hypertrichosis (6.93%), and drug discontinuation (2.79%). The overall adverse events rate was 3.69%, but there was significant heterogeneity in the rates of different adverse events. In conclusion, the present study suggests that spironolactone is an effective and safe treatment option for hair loss. However, further research is needed to fully understand the heterogeneity of treatment response and adverse events and identify factors that may predict treatment response.